Growth Hormone Improves Social Impairments From Autism Linked Disorder
New research has found that a growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome. The pilot study, conducted at the Icahn School of Medicine at Mount Sinai, focused on the use of insulin-like growth factor-1 (IGF-1) to treat Phelan-McDermid syndrome (PMS), a disorder caused by a deletion or mutation of the SHANK3 gene on chromosome 22. “Ours is the first controlled trial of any treatment for Phelan-McDermid syndrome,” said Alexander Kolevzon, MD, clinical director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai.
- Dr. Alexander Kolevzon, Associate Professor, Psychiatry, Pediatrics, Clinical Director, the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai
Additional Coverage:
Business Standard
News-Medical
Medical Xpress
Zee News

Mount Sinai Implements Own the Bone® Program for Fragility Fracture Patients
Jul 08, 2025 View All Press Releases
Mount Sinai Establishes Steven S. Elbaum Family Center for Caregiving
May 20, 2025 View All Press Releases
Mount Sinai Surgeons Perform First Heart-Liver-Kidney Transplants in New York State
May 20, 2025 View All Press Releases